|
10087
|
CYD-TDV Dengvaxia
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Approved
|
Sanofi Pasteur
|
2015
|
France
|
9 - 45 years
|
3 doses 6 months apart
|
Subcutaneous
|
NA
|
Dengue virus serotypes (1, 2, 3 and 4)
|
17D vaccine vector expressing genes of DENV-1, 2, 3, or 4
|
US FDA
|
NA
|
NA
|
NA
|
30684747
|
NCT02747927
|
https://www.sciencedirect.com/science/article/pii/S1201971219300402
|
https://www.fda.gov/media/124379/download
|
|
10210
|
DENV-1 PIV
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Inactivated
|
Phase 1
|
US Army Medical Research and Development Command
|
2015
|
USA
|
18 - 50 years
|
2 doses 28 days apart
|
Intramuscular
|
NA
|
Dengue virus serotypes -1
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NCT01502735
|
https://clinicaltrials.gov/ct2/show/NCT01502735?recrs=abde&cond=dengue+fever&phase=0123&draw=2&rank=5
|
NA
|
|
10211
|
rDEN3delta30/31-7164
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 1
|
National Institute of Allergy and Infectious Diseases
|
2013
|
USA
|
18 - 50 years
|
NA
|
Subcutaneous
|
NA
|
Dengue virus serotypes -3
|
NA
|
NA
|
Johns Hopkins Bloomberg School of Public Health
|
NA
|
NA
|
NA
|
NCT00831012
|
https://clinicaltrials.gov/ct2/show/NCT00831012?recrs=abde&cond=dengue+fever&phase=0123&draw=2&rank=12
|
NA
|
|
10295
|
DSV4
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Subunit vaccine
|
Phase 2
|
Panacea Biotec Ltd
|
NA
|
India
|
2 - 60 years
|
NA
|
NA
|
NA
|
Chimeric protein containing vHBsAg,DS, unique tetravalent dengue antigen
|
Produced using the methylotrophic yeast Pichia pastoris
|
NA
|
NA
|
NA
|
NA
|
30684747
|
NA
|
https://www.sciencedirect.com/science/article/pii/S1201971219300402
|
NA
|
|
10364
|
TAK-003
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 3
|
Takeda Pharmaceutical Company Limited
|
NA
|
USA
|
4 - 16 years
|
NA
|
Subcutaneous
|
NA
|
Dengue virus serotypes (1, 2, 3 and 4)
|
Mammalian cell vero culture
|
NA
|
NA
|
NA
|
TDV
|
30684747
|
NA
|
https://www.sciencedirect.com/science/article/pii/S1201971219300402
|
NA
|
|
10365
|
TV-003/005
|
Dengue fever
|
Hemorrhagic
|
Dengue virus
|
positive-sense, single-stranded RNA
|
Live-attenuated
|
Phase 3
|
Merck & Co. Inc.
|
NA
|
Brazil
|
2 - 59 years
|
NA
|
Subcutaneous
|
NA
|
Dengue virus serotypes (1, 2, 3 and 4)
|
Mammalian cell vero culture
|
NA
|
National Institute of Allergy and Infectious Diseases
|
NA
|
TetraVax-DV
|
30684747
|
NCT02406729
|
https://www.sciencedirect.com/science/article/pii/S1201971219300402
|
https://clinicaltrials.gov/ct2/show/NCT02406729
|